Inhibition of von Willebrand factor-platelet glycoprotein Ib interaction prevents and reverses symptoms of acute acquired thrombotic thrombocytopenic purpura in baboons

Blood

Volumn 120, Issue 17, 2012, Pages 3611-3614

  Feys, Hendrik B ^a   Roodt, Jan ^b,c,e   Vandeputte, Nele ^a   Pareyn, Inge ^a   Mottl, Harald ^d   Hou, Sam ^d   Lamprecht, Seb ^b   Van Rensburg, Walter J ^b   Deckmyn, Hans ^a   Vanhoorelbeke, Karen ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b UNIVERSITY OF THE FREE STATE   (South Africa)

^c Universitas Private Hospital   (South Africa)

^d Glenmark Pharmaceuticals SA   (Switzerland)

^e Rode Kruis Vlaanderen   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ADAMTS13 ANTIBODY; GBR 600; GLYCOPROTEIN IB; HAPTOGLOBIN; HEMOGLOBIN; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BABOON; CONTROLLED STUDY; CONVALESCENCE; DISEASE SEVERITY; HEMOGLOBIN BLOOD LEVEL; HEMOLYTIC ANEMIA; NONHUMAN; PLASMAPHERESIS; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; SYMPTOM; THROMBOCYTE COUNT; THROMBOCYTOPENIA; THROMBOTIC THROMBOCYTOPENIC PURPURA;

EID: 84868582483     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-04-421248     Document Type: Article

References (12)

1. George JN. How I treat patients with thrombotic thrombocytopenic purpura: 2010. Blood. 2010;116(20):4060-4069.
2. Noris P, Balduini CL. Investigational drugs in thrombotic thrombocytopenic purpura. Expert Opin Investig Drugs. 2011;20(8):1087-1098.
3. Wu D, Meiring M, Kotze HF, Deckmyn H, Cauwenberghs N. Inhibition of platelet glycoprotein Ib, glycoprotein IIb/IIIa, or both by monoclonal antibodies prevents arterial thrombosis in baboons. Arterioscler Thromb Vasc Biol. 2002;22(2):323-328. (Pubitemid 34127047)
4. Ulrichts H, Silence K, Schoolmeester A, et al. Antithrombotic drug candidate ALX-0081 shows superior preclinical efficacy and safety compared with currently marketed antiplatelet drugs. Blood. 2011;118(3):757-765.
5. Diener JL, Daniel Lagassé HA, Duerschmied D, et al. Inhibition of von Willebrand factor-mediated platelet activation and thrombosis by the anti-von Willebrand factor A1-domain aptamer ARC1779. J Thromb Haemost. 2009;7(7):1155-1162.
6. Fujimura Y, Usami Y, Titani K, et al. Studies on anti-von Willebrand factor (vWF) monoclonal antibody NMC-4, which inhibits both ristocetin- and botrocetin-induced vWF binding to platelet glycoprotein Ib. Blood. 1991;77(1):113-120.
7. Feys HB, Roodt J, Vandeputte N, et al. Thrombotic thrombocytopenic purpura directly linked with ADAMTS13 inhibition in the baboon (Papio ursinus). Blood. 2010;116(12):2005-2010.
8. Feys HB, Liu F, Dong N, et al. ADAMTS-13 plasma level determination uncovers antigen absence in acquired thrombotic thrombocytopenic purpura and ethnic differences. J Thromb Haemost. 2006;4(5):955-962.
9. Vanhoorelbeke K, Cauwenberghs N, Vauterin S, et al. A reliable and reproducible ELISA method to measure ristocetin cofactor activity of von Willebrand factor. Thromb Haemost. 2000;83(1):107-113. (Pubitemid 30045485)
10. De Meyer SF, Vandeputte N, Pareyn I, et al. Restoration of plasma von Willebrand factor deficiency is sufficient to correct thrombus formation after gene therapy for severe von Willebrand disease. Arterioscler Thromb Vasc Biol. 2008;28(9):1621-1626.
11. Jilma-Stohlawetz P, Gilbert JC, Gorczyca ME, Knöbl P, Jilma B. A dose ranging phase I/II trial of the von Willebrand factor inhibiting aptamer ARC1779 in patients with congenital thrombotic thrombocytopenic purpura. Thromb Haemost. 2011;106(3):539-547.
12. Cataland SR, Peyvandi F, Mannucci PM, et al. Initial experience from a double-blind, placebo-controlled, clinical outcome study of ARC1779 in patients with thrombotic thrombocytopenic purpura. Am J Hematol. 2012;87(4):430-432.